CIDARA THERAPEUTICS INC (CDTX) Fundamental Analysis & Valuation

NASDAQ:CDTX • US1717572069

221.38 USD
+0.06 (+0.03%)
At close: Jan 6, 2026
221.38 USD
0 (0%)
After Hours: 1/6/2026, 8:19:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CDTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

CDTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. CDTX has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CDTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. CDTX Profitability Analysis

1.1 Basic Checks

  • CDTX had negative earnings in the past year.
  • CDTX had a negative operating cash flow in the past year.
  • In the past 5 years CDTX always reported negative net income.
  • CDTX had a negative operating cash flow in each of the past 5 years.
CDTX Yearly Net Income VS EBIT VS OCF VS FCFCDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of CDTX (-35.62%) is better than 61.89% of its industry peers.
  • CDTX has a Return On Equity of -43.74%. This is in the better half of the industry: CDTX outperforms 69.25% of its industry peers.
Industry RankSector Rank
ROA -35.62%
ROE -43.74%
ROIC N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDTX Yearly ROA, ROE, ROICCDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

  • CDTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDTX Yearly Profit, Operating, Gross MarginsCDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CDTX Health Analysis

2.1 Basic Checks

  • CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CDTX has been increased compared to 1 year ago.
  • The number of shares outstanding for CDTX has been increased compared to 5 years ago.
  • Compared to 1 year ago, CDTX has an improved debt to assets ratio.
CDTX Yearly Shares OutstandingCDTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CDTX Yearly Total Debt VS Total AssetsCDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • CDTX has an Altman-Z score of 41.23. This indicates that CDTX is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 41.23, CDTX belongs to the best of the industry, outperforming 95.66% of the companies in the same industry.
  • CDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 41.23
ROIC/WACCN/A
WACC8.88%
CDTX Yearly LT Debt VS Equity VS FCFCDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • CDTX has a Current Ratio of 4.62. This indicates that CDTX is financially healthy and has no problem in meeting its short term obligations.
  • CDTX's Current ratio of 4.62 is in line compared to the rest of the industry. CDTX outperforms 53.58% of its industry peers.
  • CDTX has a Quick Ratio of 4.62. This indicates that CDTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.62, CDTX is in line with its industry, outperforming 55.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 4.62
CDTX Yearly Current Assets VS Current LiabilitesCDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CDTX Growth Analysis

3.1 Past

  • CDTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.23%.
  • Looking at the last year, CDTX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
  • CDTX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.85% yearly.
EPS 1Y (TTM)-70.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.53%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%N/A

3.2 Future

  • CDTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.49% yearly.
  • CDTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 159.31% yearly.
EPS Next Y27.77%
EPS Next 2Y20.11%
EPS Next 3Y12.81%
EPS Next 5Y21.49%
Revenue Next Year-100%
Revenue Next 2Y10.59%
Revenue Next 3Y13.33%
Revenue Next 5Y159.31%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CDTX Yearly Revenue VS EstimatesCDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CDTX Yearly EPS VS EstimatesCDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. CDTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CDTX. In the last year negative earnings were reported.
  • Also next year CDTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDTX Price Earnings VS Forward Price EarningsCDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDTX Per share dataCDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • CDTX's earnings are expected to grow with 12.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.11%
EPS Next 3Y12.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CDTX Dividend Analysis

5.1 Amount

  • CDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CDTX Fundamentals: All Metrics, Ratios and Statistics

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (1/6/2026, 8:19:29 PM)

After market: 221.38 0 (0%)

221.38

+0.06 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners103.66%
Inst Owner Change-1.41%
Ins Owners0.53%
Ins Owner Change-1.72%
Market Cap6.96B
Revenue(TTM)N/A
Net Income(TTM)-184.74M
Analysts74.29
Price Target220.19 (-0.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-125.8%
Max EPS beat(2)18.65%
EPS beat(4)2
Avg EPS beat(4)-24.63%
Min EPS beat(4)-125.8%
Max EPS beat(4)54.07%
EPS beat(8)5
Avg EPS beat(8)-119.11%
EPS beat(12)7
Avg EPS beat(12)-61.98%
EPS beat(16)10
Avg EPS beat(16)-42.61%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)63.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.01%
EPS NY rev (1m)0%
EPS NY rev (3m)-35.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.48
P/tB 16.48
EV/EBITDA N/A
EPS(TTM)-11.78
EYN/A
EPS(NY)-6.4
Fwd EYN/A
FCF(TTM)-4.23
FCFYN/A
OCF(TTM)-4.23
OCFYN/A
SpS0
BVpS13.43
TBVpS13.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.62%
ROE -43.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 4.62
Altman-Z 41.23
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)188.62%
Cap/Depr(5y)130.51%
Cap/Sales(3y)3.7%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.53%
EPS Next Y27.77%
EPS Next 2Y20.11%
EPS Next 3Y12.81%
EPS Next 5Y21.49%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y10.59%
Revenue Next 3Y13.33%
Revenue Next 5Y159.31%
EBIT growth 1Y-232.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.86%
EBIT Next 3Y-11.38%
EBIT Next 5YN/A
FCF growth 1Y-328.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-332.86%
OCF growth 3YN/A
OCF growth 5YN/A

CIDARA THERAPEUTICS INC / CDTX FAQ

What is the ChartMill fundamental rating of CIDARA THERAPEUTICS INC (CDTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CDTX.


What is the valuation status of CIDARA THERAPEUTICS INC (CDTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to CIDARA THERAPEUTICS INC (CDTX). This can be considered as Overvalued.


How profitable is CIDARA THERAPEUTICS INC (CDTX) stock?

CIDARA THERAPEUTICS INC (CDTX) has a profitability rating of 1 / 10.


What is the financial health of CIDARA THERAPEUTICS INC (CDTX) stock?

The financial health rating of CIDARA THERAPEUTICS INC (CDTX) is 7 / 10.